Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع الأدوية المهني - professional drug store - nystatin 10.000000 iu/100g, gramicidin 0.025 g/100g, neomycin 0.25 g/100g, triamcinolone acetonide 0.1 g/100g - 10.000000 iu/100g, 0.025 g/100g, 0.25 g/100g, 0.1 g/100g

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع الأدوية المهني - professional drug store - nystatin 10.000000 iu/100g, gramicidin 0.025 g/100g, neomycin 0.25 g/100g, triamcinolone acetonide 0.1 g/100g - 10.000000 iu/100g, 0.025 g/100g, 0.25 g/100g, 0.1 g/100g

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الدولية للدواء - pharma international company - radix scutellaria crude powder 0.225 g/15gm, cortex phellodendri crude powder 0.225 g/15gm, rhizoma coptidis crude powder 0.15 g/15gm - 0.225 g/15gm, 0.225 g/15gm, 0.15 g/15gm

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الدولية للدواء - pharma international company - b-sitosterol 0.1875 g/75gm, radix scutellaria crude powder 1.125 g/75gm, cortex phellodendri crude powder 1.125 g/75gm, rhizoma coptidis crude powder 0.75 g/75gm - 0.1875 g/75gm, 1.125 g/75gm, 1.125 g/75gm, 0.75 g/75gm

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية أدونيس - adonis drug store - piperacillin 2 g, tazobactam 0.25 g - 2 g, 0.25 g

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - l-arginine hydrochloride; l-lysine hydrochloride - infusion, solution - l-arginine hydrochloride 25 g/l; l-lysine hydrochloride 25 g/l

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - tazobactam 0.25 g, piperacillin monohydrate 2 g - 0.25 g, 2 g

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

modern pharmaceutical company hungary - 25 g aluminium tube with applicator - ointment - 0.75 g/ 25 g - medical devices-medical devices

Philippines - English - FDA (Food And Drug Administration)

ccm international (philippines), inc - zinc oxide , calamine - cream - 3g/4g/25g

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - piperacillin sodium, quantity: 2.1 g (equivalent: piperacillin, qty 2 g); tazobactam sodium, quantity: 0.27 g (equivalent: tazobactam, qty 0.25 g) - injection, powder for - excipient ingredients: - tazopip is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta -lactamase producing organisms in the conditions as listed: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated). 3.intra- abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, tazopip is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. while tazopip is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta -lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to tazopip. therapy with tazopip may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta -lactamase producing organisms listed above. however, once these results become available, appropriate therapy should be continued. in serious infections, presumptive therapy with tazopip may be initiated before susceptibility test results are available. combination therapy with tazopip and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.